

Novel ethyl p-methoxy cinnamate rich *Kaempferia galanga* (L.) essential oil and its pharmacological applications: special emphasis on anticholinesterase, anti-tyrosinase, α -amylase inhibitory, and genotoxic efficiencies

Twahira Begum^{1,2}, Roktim Gogoi^{1,2}, Neelav Sarma^{1,2},
Sudin Kumar Pandey^{1,2} and Mohan Lal¹

¹ Agrotechnology & Rural Development Division, CSIR-North East Institute of Science & Technology, Jorhat, Assam, India

² AcSIR-Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, India

ABSTRACT

Background: *Kaempferia galanga* (L.) is one of the prospective therapeutic plants with an aromatic rhizome, and belongs to the Zingiberaceae family. This herb is commonly used by local practitioners in traditional Asian medicine.

Methods: In the present investigation, the novel *Kaempferia galanga* rhizome essential oil rich in ethyl p-methoxy cinnamate (EMCKG) was evaluated using GC/MS for chemical composition analysis. EMCKG was analyzed for its possible antimicrobial, neurodegenerative inhibitory, acetylcholinesterase, anti-inflammatory, and antioxidant activities as well as for the genotoxic effects using the standard methodologies. ANOVA and *post hoc* was performed to test the statistical significance of the study.

Results: GC/MS analysis identified ethyl p-methoxy cinnamate as the major component of EMCKG essential oil with an area percentage of 66.39%. The EMCKG exhibited moderate (DPPH assay $IC_{50} = 15.64 \pm 0.263 \mu\text{g/mL}$; ABTS assay $IC_{50} = 16.93 \pm 0.228 \mu\text{g/mL}$) antioxidant activity than standard ascorbic acid (DPPH assay $IC_{50} = 21.24 \pm 0.413 \mu\text{g/mL}$; ABTS assay $IC_{50} = 21.156 \pm 0.345 \mu\text{g/mL}$). Similarly, EMCKG showed comparable activity in albumin denaturation ($IC_{50} = 2.93 \pm 0.59 \mu\text{g/mL}$) and protease inhibitor assay ($IC_{50} = 17.143 \pm 0.506 \mu\text{g/mL}$) to that of standard sodium diclofenac ($IC_{50} = 23.87 \pm 0.729 \mu\text{g/mL}$ and $IC_{50} = 19.18 \pm 0.271 \mu\text{g/mL}$, respectively). The EMCKG exhibited a dose-dependent antimicrobial activity pattern with the highest inhibitory activity at 500 $\mu\text{g/mL}$ against *Staphylococcus aureus* and considerable anticholinesterase activities ($IC_{50} = 21.94 \pm 0.109 \mu\text{g/mL}$) compared to the standard galanthamine ($IC_{50} = 27.18 \pm 0.511 \mu\text{g/mL}$). EMCKG also showed strong anti-diabetic activity ($IC_{50} = 18.503 \pm 0.480 \mu\text{g/mL}$) and anti-tyrosinase activity ($IC_{50} = 14.756 \pm 0.325 \mu\text{g/mL}$) as compared to the standards used (acarbose $IC_{50} = 20.39 \pm 0.231 \mu\text{g/mL}$ and kojic acid $IC_{50} = 17.73 \pm 0.192 \mu\text{g/mL}$) in the study. Genotoxicity analysis of EMCKG revealed that at 1 $\mu\text{g/mL}$ concentration has no toxic effects in mitosis of *Allium cepa* roots (Mitotic Index MI = 13.56% and chromosomal aberration CA = 07.60%). The ANOVA confirmed

Submitted 29 August 2022
Accepted 30 November 2022
Published 9 January 2023

Corresponding author
Mohan Lal,
drmohanlal80@gmail.com

Academic editor
Héctor Mora-Montes

Additional Information and
Declarations can be found on
page 18

DOI 10.7717/peerj.14606

© Copyright
2023 Begum et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

that except for the anticholinesterase activity, there is insignificant difference for essential oil and standards used for all the other bioactivities thus confirming their interchangeable applicability.

Conclusions: Current research provides the basis for the fact that besides being a rich source of ethyl p-methoxycinnamate, EMCKG has the potential for future formulation and development of an inexpensive skin-care agent and for the preparation of anti-diabetic drugs.

Subjects Biochemistry, Cell Biology, Microbiology

Keywords Anti-diabetic, Antimicrobial, Essential oil, Genotoxicity, Neurodegenerative, Ethyl p-methoxycinnamate

INTRODUCTION

Medicinal and aromatic herbs have been utilized extensively for traditional medical practices since antiquity and are now used extensively in modern medicine. These pharmacologically active and aromatic plants provide raw materials for usage by various pharmaceutical companies operating in drug research (Begum, Gogoi & Lal, 2020; Gogoi, Begum & Lal, 2020). The medicinal values of the plants can be ascribed to their constituent bioactive compounds (Aiyelaagbe & Osamudiamen, 2009). *Kaempferia galanga* (L.) is a high-value aromatic medicinal plant with numerous uses from its medicinal properties point of view. It is an aromatic rhizomatous herb belonging to the Zingiberaceae family. The name of the plant was cross-checked with <http://www.theplantlist.org> on 1st March 2021. The rhizome is tuberous with a camphoraceous odor along with some bitter aromatic taste. It is distributed widely in the tropics and sub-tropics of Asia as well as Africa (Geetha et al., 1997; Munda, Saikia & Lal, 2018). It is native to India, Thailand, Malaysia, Taiwan, and southern China of tropical Asia (Mitra, Orbell & Muralitharan, 2007; Techaprasan et al., 2010). For medicinal purposes, *K. galanga* finds its traditional use for treating headaches, inflammation, colds, asthma, hypertension, indigestion, tumor, pectoral and abdominal pains, rheumatism, and dyspepsia (Hu, 2005; Sulaiman et al., 2008; Munda, Saikia & Lal, 2018). It also finds its use in aromatherapy as well as for stress relieving, depression, anxiety and restlessness (Kanjanapothi et al., 2004; Hu, 2005; Sulaiman et al., 2008; Chan et al., 2009; Liu et al., 2010).

The economically valuable plant component of *K. galanga* is the rhizome. Due to its numerous pharmacological characteristics, the rhizome, which contains essential oil, is in high demand in the industrial sector. *K. galanga* essential oil consists of many bioactive compounds which are responsible for their various medicinal applications. The characteristics flavors and odors of essential oils are released on essential oil emission (Begum et al., 2022). Ethyl p-methoxycinnamate is one of the compounds present in *K. galanga* which possesses highly valuable medicinal properties (Munda, Saikia & Lal, 2018; Mahanta et al., 2020). The ethyl p-methoxycinnamate derived from the plant finds its wide use in medicines for its skin whitening activity, antibacterial, antiangiogenic, anti-inflammatory, anticancer and insecticidal properties and its varied use in cosmetics and food industries also (Pandji et al., 1993; Huang, Yagura & Chen, 2008; Mahanta et al.,

2020). The ethyl p-methoxycinnamate compound also possesses the sedative properties of *K. galanga* by inhibiting locomotors' activities (Umar et al., 2011). A previous study has reported that ethyl p-methoxycinnamate is capable of significantly decreasing the melanin synthesis level in α -melanocyte stimulated B16F10 murine melanoma cells (Ko et al., 2014). A copper-containing enzyme tyrosinase is one of the most important catalysts in melanin biosynthesis. The melanin accumulation in the skin is due to the activity of this enzyme. However, hyperpigmentation *i.e.*, melanin accumulation in the skin paves the way for numerous skin ailments like freckles, age spots, melasma, *etc.* (Karioti et al., 2007). The browning in foods associated with quality losses and disorder due to hyperpigmentation in human skin can be effectively controlled with therapeutic agents like tyrosinase inhibitors (Miyazawa et al., 2003). With emerging trends, a lighter skin tone is preferable further boosting the ever-growing cosmetic industries (Ko et al., 2014). For fulfilling these demand tyrosinase inhibitors finds wide application in the cosmetology industry. Plants have been searched for the fortuitous discovery of novel tyrosinase inhibitors since plants are rich, reliable sources of tyrosinase inhibitors with lesser side effects (Maisuthisakul & Gordon, 2009).

Studies have further revealed that ethyl p-methoxycinnamate possesses anti-hypertensive, anti-ulcer, and anti-inflammatory properties also. The plant also finds wide application in the cure of inflammatory conditions, lipid disorders, and diabetes mellitus (Mangaly & Sabu, 1991; Jitoe et al., 1992; Ogiso & Kobayashi, 1994; Choochote et al., 1999; Othman et al., 2002; Gogoi, Begum & Lal, 2020). Additionally, the compound has shown high cytotoxicity toward *HeLa* cells (Riditid et al., 2008). Another study by resazurin microtitre assay has revealed that ethyl p-methoxycinnamate is capable of inhibiting drug-susceptible multidrug-resistant strain of *Mycobacterium tuberculosis* (Lakshmanan et al., 2011). Thus, *K. galanga* with high content of ethyl p-methoxycinnamate would be highly valuable owing to its various pharmaceutical uses.

More recently the incidence of multidrug resistance has been on the rise and hence in light of this source of natural resources with effective pharmacological properties is the need of the hour. The compound ethyl p-methoxycinnamate is widely used in cosmetics (Taufikkurohmah, 2005). Moreover, it is also found to possess anti-microbial, nematicidal, anti-neoplastic mosquito-repellent and effects (Kanjanapothi et al., 2004; Kim et al., 2008; Sutthanont et al., 2010; Liu et al., 2010; Hong et al., 2011). From the pharmacological point of view, it is a strong antifungal agent as previously found in various studies. Hence, our present study is aimed at extraction of the essential oil of ethyl p-methoxycinnamate rich *K. galanga*, and analysis of its chemical composition along with evaluation for antioxidant, anti-inflammatory, antimicrobial, skin whitening ability, genotoxicity, anti-cholinesterase and anti-diabetic activity. The experiment was designed to see the effect of other compounds on ethyl-p-methoxy cinnamate pharmacological potentials. Previously high rhizome and high essential oil yielding varieties of *K. galanga* have been developed namely, 'Jor Lab K-1' and 'Jor Lab Bharamaputra-1' respectively (Lal et al., 2017; Lal, 2019a, 2019b). However, so far none of the ethyl p-methoxycinnamate compound-rich *K. galanga* is available in the public sphere. So, in the present study is the first of its kind for ethyl p-methoxycinnamate rich EMCKG along with their pharmacological properties screening

for validating their industrial application. The results could be a base source for pharmaceutical products however, after proper investigation safe drugs can be developed for commercial scale.

MATERIALS AND METHODS

Chemicals used in the study

The chemicals used were HPLC grade methanol and ethanol; potassium ferricyanide ($K_3Fe(CN)_6$); aluminum chloride ($AlCl_3$); tris-buffer ($C_4H_{11}NO_3$); ethyl methanesulfonate ($C_3H_8O_3S$); ascorbic acid ($C_6H_8O_6$); sodium carbonate (Na_2CO_3); ferric chloride ($FeCl_3$); acetocarmine (CH_3CO_2H); ethylene diamine tetraacetic acid (EDTA) ($C_{10}H_{16}N_2O_8$); 2,2-diphenyl 1 picrylhydrazyl ($C_{18}H_{12}N_5O_6$); potassium persulfate ($K_2S_2O_8$); MHA-Mueller Hinton Agar and PDA-Potato Dextrose agar were procured from HiMedia (India). ABTS (2, 2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) ($C_{18}H_{18}N_4O_6S_4$); trichloroacetic acid ($C_2HCl_3O_2$); ferrous chloride ($FeCl_2$), ferrozine ($C_{20}H_{12}N_4Na_2O_6S_2$) and diclofenac sodium salt ($C_{14}H_{10}Cl_2NNaO_2$) were purchased from Sigma Aldrich (Germany). A fresh egg of a hen used for albumin and all the other unlabeled chemicals were obtained from the market of Jorhat, Assam India.

Plant material collection and extraction of essential oil

Ethyl p-methoxycinnamate rich *K. galanga* L. (cv. Jor Lab K-2) is cultivated at the experimental farm of CSIR-NEIST, Jorhat, India (26°44'00.0" N, 94°09'50.0" E) under the supervision of the plant breeder Dr. Mohan Lal, CSIR-NEIST Jorhat. A voucher specimen was placed in the CSIR-NEIST Jorhat departmental herbarium vide herbarium no RRLJKN-17. For the essential oil isolation matured rhizomes of *K. galanga* (cv. Jor Lab K-2) were harvested during December 2020. Collected rhizomes were washed, to remove the sand particles which were cut into smaller slices. The sliced rhizomes were shade dried for 7 days followed by oven drying at the temperature of 70 °C for 3 days until a constant mass was obtained. The essential oil was isolated from dried rhizomes using the Clevenger apparatus as per Lal (2019a).

GC/MS analysis of *Kaempferia galanga* essential oil

The GC/MS analysis of EMCKG was done as per Begum et al. (2022).

GC/MS	Agilent technologies gas chromatograph
Column	HP-5MS (30 m × 0.25 mm i.d.; film thickness 0.25 μm)
Detector	MSD 5975 C
Carrier gas	Helium (1 mL/min flow rate)
Temperature range	40 °C (2 min) followed by 25 °C with a rate of 5 °C/min and lastly 300 °C at 30 °C/min (10 min)
Scanning range	45 to 650 amu

Protein (egg albumin) denaturation assay

The EMCKG was evaluated for anti-inflammatory activity as per [Gogoi et al. \(2020a\)](#). The EMCKG was analyzed at a varying concentration ranging from 50 to 300 µg/mL for anti-inflammatory activity. IC₅₀ *i.e.*, 50% inhibition was analyzed using MS Excel.

Protease inhibitor activity

Protease inhibitor activity was analyzed using a standard method as per [Gogoi et al. \(2020b\)](#). For the analysis, EMCKG was prepared with different concentrations which ranged from 1.5 to 48 µg/mL. IC₅₀ *i.e.*, 50% inhibition was analyzed using MS Excel.

Antimicrobial activities

Microbial strains used

The EMCKG antimicrobial activities were analyzed using both gram-positive and gram-negative bacteria. The gram-positive bacteria used were *Staphylococcus aureus*, *Micrococcus luteus*, *Streptococcus mutans*, *Bacillus subtilis* and *Bacillus cereus* with ATCC-11632, ATCC-10240, ATCC-25175, ATCC-11774 and ATCC-10876, respectively. *Salmonella typhimurium* and *Salmonella enteric* with ATCC-13311, and ATCC-35664 were used as gram-negative bacteria. In addition to those four fungal strains namely, *Aspergillus niger*, *Fusarium keratoplasticum*, *Aspergillus oryzae*, *Saccharomyces cerevisiae*, *Aspergillus fumigatus*, and *Candida albicans* with ATCC-16885, ATCC-36031, ATCC-10124, ATCC-9763, ATCC-204305, ATCC-66027 respectively were employed for evaluation of the antifungal activity. Standard Ciprofloxacin (antibacterial) and Fluconazole (antifungal) each at 10 µg/disc were used as standard drugs.

DD and MIC assays

The EMCKG was analyzed for their antimicrobial activity as per [Pandey et al. \(2022\)](#). The EMCKG was analyzed for their antimicrobial activity by agar disc diffusion method at various concentrations ranging from 50 to 500 µg/mL. The minimal inhibitory concentration (MIC) was analyzed using the method of broth microdilution.

Growth curve study

The bacterial growth curve experiment was performed to analyze the bactericidal capabilities of EMCKG essential oil. The experiment was performed as per the protocol of [Huang et al. \(2018\)](#) with slight modifications. The bacteria were treated with different concentrations of the essential oil *viz.*, 50, 100, 250 and 500 µg/mL. The broth was taken as blank with a control that is free from the essential oil. Data were recorded at an interval of 1 h continuous up to 8 h. The measurements of the optical density (OD₆₀₀) were taken using the Eppendorf Bio spectrometer basic. Time was taken along the horizontal axis and the OD of the supernatants was taken against the vertical axis.

Acetylcholinesterase activity assay

The EMCKG was analyzed for acetylcholinesterase inhibitory (AChE) activity using a standard modified methodology as per [Begum et al. \(2022\)](#). The EMCKG in the amount of

50 μL was added for the reaction analysis. IC_{50} *i.e.*, 50% inhibition was analyzed using MS Excel.

Anti-diabetic analysis

The antidiabetic activity of EMCKG was analyzed using standard methodology as per [Begum et al. \(2022\)](#). For the evaluation, the EMCKG was prepared in various concentrations ranging from 5 to 30 $\mu\text{g}/\text{mL}$. IC_{50} *i.e.*, 50% inhibition was analyzed using MS Excel.

Anti-tyrosinase activity assay

Tyrosinase inhibitory assay was conducted as per [Begum et al. \(2022\)](#). For the analysis, 125 μL of EMCKG was used in the reaction involved. IC_{50} *i.e.*, 50% inhibition was analyzed using MS Excel.

Antioxidant activity

DPPH assay

DPPH free radical scavenging activity of EMCKG was performed as per [Gogoi et al. \(2020a\)](#). The EMCKG was used at a concentration ranging from 5 to 30 $\mu\text{g}/\text{mL}$. IC_{50} *i.e.*, 50% inhibition was analyzed using MS Excel.

ABTS assay

The ABTS assay was performed following the protocol as per [Dutta et al. \(2021\)](#). The EMCKG at various concentrations ranging from 10–60 $\mu\text{g}/\text{mL}$ was used for the analysis. IC_{50} *i.e.*, 50% inhibition was analyzed using MS Excel.

Metal chelating activity assay

The metal chelating activity assay was conducted for the antioxidant activity of EMCKG as per [Begum et al. \(2022\)](#). The EMCKG at various concentrations ranging from 10–60 $\mu\text{g}/\text{mL}$ was used for the analysis. IC_{50} *i.e.*, 50% inhibition was analyzed using MS Excel.

Reducing antioxidant power determination

The reducing power of EMCKG was evaluated using a standard protocol as mentioned by [Gogoi et al. \(2020b\)](#). The EMCKG at various concentrations ranging from 5–30 $\mu\text{g}/\text{mL}$ was used for the analysis. IC_{50} *i.e.*, 50% inhibition was analyzed using MS Excel.

Test for genotoxicity (Allium cepa assay)

The genotoxicity of EMCKG was analyzed using a standard method as per [Begum et al. \(2022\)](#). The EMCKG at 1 $\mu\text{g}/\text{mL}$ concentration was used for the study.

Statistical analysis

The standard deviation (SD) was analyzed using MS Excel. Each of the experiments was performed in triplicates to reduce experimental errors (when $p \leq 0.05$ the difference was considered statistically significant). The ANOVA analysis was done followed by a *post hoc* analysis.

Table 1 GC/MS analysis of essential oil of ethyl p-methoxy cinnamate rich *Kaempferia galanga* essential oil (MCKG).

Sl. no.	Name of the compound	RT	Area %	RI*	RI**	Identification method
1	α -Pinene	5.77	1.68	937	940	1,2,3
2	Camphene	6.05	1.66	952	954	1,2,3
3	3-Carene	7.18	9.60	1,011	1,006	1,2,3
4	p-Cymene	7.44	1.12	1,025	1,022	1,2
5	D-Limonene	7.52	1.06	1,030	1,028	1,2,3
6	Eucalyptol	7.58	1.24	1,032	1,033	1,2,3
7	<i>cis</i> -p-Mentha-2,8-dien-1-ol	8.84	0.80	1,122	1,123	1,2
8	endo-Borneol	10.12	2.76	1,167	1,064	1,2
9	Bornyl acetate	12.26	0.72	1,285	1,283	1,2
10	<i>trans</i> , Ethyl cinnamate	15.18	9.86	1,464	1,462	1,2,3
11	Pentadecane	15.63	1.00	1,500	1,497	1,2,3
12	Ethyl p-methoxycinnamate	19.40	66.39	1,785	1,781	1,2,3
13	Benzyl Benzoate	19.57	0.49	1,762	1,763	1,2

Total = 100%, Identified compounds = 98.38%, Unidentified compounds = 1.62%

Monoterpene hydrocarbons (Sl No. 1-5) = 15.12%

Oxygenated monoterpene (Sl No. 6, 8) = 4.00%

Monoterpenoid (Sl No. 9) = 0.72%

Sesquiterpenes hydrocarbons (Sl No. 11) = 1.00%

Cinnamic acid esters (Sl No. 10, 12) = 76.25%

Benzoate ester (Sl No. 13) = 0.49%

Others (Sl No. 7) = 0.80%

Note:

RI*, Retention Index Literature (Goodner, 2007; Kovats, 1965); RI**, Retention Index Experimental; RT, Retention time; MCKG, ethyl p-methoxy cinnamate rich *Kaempferia galanga* essential oil, 1. Comparison of retention indices with literatures, 2. Comparison of the mass spectra with the mass libraries, 3. Comparing retention time with standards injected with same GC condition.

RESULTS**GC/MS analysis of *K. galanga* essential oil**

The GC/MS analysis report of the EMCKG revealed ethyl p-methoxy cinnamate (66.39%) as the primary major compound followed by *trans*, ethyl cinnamate (9.86%) and 3-carene (9.60%). The other compounds present were in minor (<5%) amounts. The minor compounds present were endo-borneol (2.76%), camphene (1.66%), α -pinene (1.68%), eucalyptol (1.24%), benzyl benzoate (0.49%), *p*-cymene (1.12%), D-limonene (1.06%), pentadecane (1.00%), *cis*-p-mentha-2,8-dien-1-ol (0.80%), and bornyl acetate (0.72%) (Table 1). The cinnamic acid esters composed a majority of the component of EMCKG constituting 76.25% of the total identified compounds followed by monoterpene hydrocarbon (15.12%), oxygenated monoterpene (4.00%), sesquiterpene hydrocarbon (1.00%), monoterpenoid (0.72%) and lastly benzoate ester (0.49%).

Table 2 50% Inhibition concentrations (IC₅₀) determination values for pharmacological activities of MCKG and standards using MS-EXCEL software.

Essential oil/ Standard	DPPH scavenging (µg/mL)	ABTS scavenging (µg/mL)	Metal chelating (µg/mL)	Protein denaturation (µg/mL)	Protease inhibitory (µg/mL)	Tyrosinase inhibitory (µg/mL)	Acetylcholinesterase inhibitory (µg/mL)	α-Amylase inhibitory (µg/mL)
MCKG	15.64 ± 0.263	16.93 ± 0.228	19.29 ± 0.805	2.93 ± 0.59	17.143 ± 0.506	14.756 ± 0.325	21.94 ± 0.109	18.503 ± 0.480
Ascorbic acid	21.24 ± 0.413	21.156 ± 0.345	nd	nd	nd	nd	nd	nd
EDTA	nd	nd	30.72 ± 0.834	nd	nd	nd	nd	nd
Sodium diclofenac	nd	nd	nd	19.18 ± 0.271	23.87 ± 0.729	nd	nd	nd
Kojic acid	nd	nd	nd	nd	nd	17.73 ± 0.192	nd	nd
Galanthamine hydrobromide	nd	nd	nd	nd	nd	nd	27.18 ± 0.511	nd
Acarbose	nd	nd	nd	nd	nd	nd	nd	20.39 ± 0.231

Note:

µg, microgram; mL, millilitre; SD, standard deviation; IC₅₀, 50% of Inhibition concentration; %, percentage; MCKG, ethyl p-methoxycinnamate rich *K. galanga* essential oil; nd, not determined.

Anti-inflammatory activity

The EMCKG was analyzed for anti-inflammatory activity using two different methods albumin denaturation assay and protease inhibitor activity assay. The EMCKG showed anti-inflammatory activity with an IC₅₀ value of 2.93 µg/mL as compared to that of standard sodium diclofenac 19.18 µg/mL for protein denaturation assay, while protease inhibitor assay revealed IC₅₀ of 17.14 µg/mL for EMCKG and 23.87 µg/mL for standard sodium diclofenac (Table 2).

Antimicrobial activity

The study reveals that the *K. galanga* essential oil exhibited antimicrobial activity in a concentration-dependent manner with the highest inhibition zone at 500 µg/mL while the lowest activity was at 50 µg/mL (Table 3). The MIC revealed that *K. galanga* essential oil exhibited prominent antibacterial activity as compared to antifungal activity (Table 4).

The bacterial growth curve assay further revealed the potent antimicrobial activity of EMCKG. The experiment showed that the growth curve of the control increases with time, however, the results were different in the essential oil treatments. In the case of the addition of ethyl p-methoxy cinnamate-rich *K. galanga* essential oil at different concentrations, the growth of the bacteria took a longer time or in higher concentrations, its growth stopped which means the essential oil hampered the lag and log phase. It is seen that the essential oil is effective towards all the bacteria in high concentrations and in lower concentrations it somehow affects the growth of the bacteria which is in the same line with the other antimicrobial activity performed (Fig. 1).

Anti-cholinesterase activity

The anticholinesterase activity of the *K. galanga* essential oil was analyzed using standard methodology. For the assay, the IC₅₀ value for standard galanthamine was 27.18 µg/mL whereas the essential oil sample showed an IC₅₀ value of 21.94 µg/mL as analyzed by MS-Excel (Table 2).

Table 3 Antimicrobial activity of ethyl p-methoxy cinnamate rich *K. galanga* essential oil.

Name of the essential oil	Bacteria/Fungus	Inhibition zone (mm)				Standard diameter in mm (ciprofloxacin/Fluconazol, 10 µg/mL)
		50 µg/mL	100 µg/mL	250 µg/mL	500 µg/mL	
MCKG	<i>S. aureus</i>	13 ± 0.58	20 ± 1.5	27 ± 1.2	35 ± 1.5	18 ± 1
	<i>B. subtilis</i>	10 ± 1	13 ± 1.52	25 ± 0.6	31 ± 1.52	38 ± 1.53
	<i>B. cereus</i>	14 ± 1.53	15 ± 2.08	20 ± 1.2	26 ± 1.15	15 ± 1.52
	<i>S. typhimurium</i>	12 ± 1.15	15 ± 1.52	19 ± 1	20 ± 1.52	19 ± 0.58
	<i>M. luteus</i>	8 ± 0.5	12 ± 0.5	18 ± 0.5	22 ± 0.5	44 ± 1.15
	<i>S. mutans</i>	8 ± 0.5	9 ± 0.5	11 ± 0.5	14 ± 1	25 ± 1
	<i>S. enterica</i>	10 ± 0.5	11 ± 0.5	12 ± 0.5	14 ± 0.5	30 ± 1.20
	<i>S. cereviaceae</i>	17 ± 0.5	19 ± 0.5	21 ± 0.5	24 ± 0.5	27 ± 0.5
	<i>C. albicans</i>	11 ± 0.5	15 ± 0.5	17 ± 0.5	21 ± 0.5	29 ± 0.5
	<i>A. oryzae</i>	7 ± 0.5	9 ± 0.5	16 ± 0.5	19 ± 0.5	10 ± 1.25
	<i>F. keratoplasticum</i>	NA	10 ± 0.5	12 ± 0.5	16 ± 0.5	28 ± 0.50
	<i>A. fumigatus</i>	NA	NA	11 ± 0.5	13 ± 0.5	21 ± 0.5
	<i>A. niger</i>	NA	NA	NA	10 ± 0.5	26 ± 0.47

Note:
µg, microgram; mL, millilitre; MCKG, ethyl p-methoxycinnamate rich *K. galanga* essential oil.

Table 4 Minimum inhibitory concentration (MIC) for ethyl p-methoxy cinnamate rich *K. galanga* essential oil.

Microbial strains	MIC values (µg/mL) MCKG	MIC values (µg/mL) ciprofloxacin	MIC values (µg/mL) fluconazole
<i>B. cereus</i>	48.00	03.50	NA
<i>S. aureus</i>	12.50	08.20	NA
<i>M. luteus</i>	10.50	12.50	NA
<i>B. subtilis</i>	8.50	12.15	NA
<i>S. typhimurium</i>	8.50	10.25	NA
<i>S. enterica</i>	8.25	15.25	NA
<i>S. mutans</i>	5.25	08.50	NA
<i>A. oryzae</i>	15.50	NA	12.25
<i>A. fumigatus</i>	10.25	NA	15.55
<i>S. cereviaceae</i>	8.50	NA	10.25
<i>A. niger</i>	6.75	NA	15.50
<i>C. albicans</i>	6.25	NA	08.10
<i>F. keratoplasticum</i>	6.25	NA	15.00

Note:
µg, microgram; mL, millilitre; MCKG, ethyl p-methoxycinnamate rich *K. galanga* essential oil.

Anti-diabetic activity

Ethyl p-methoxy cinnamate-rich *K. galanga* essential oil was analyzed for its anti-diabetic activity using α -amylase inhibitory activity assay. The IC₅₀ value for EMCKG was found to be 18.50 µg/mL while for the standard it was found to be 20.39 µg/mL (Table 2).




Figure 1 The bacterial growth curves affected by ethyl p-methoxycinnamate rich *K. galanga* essential oil. (A) *B. subtilis*, Scatterplot of multiple variables against Time. ??????1 in *B. subtilis* growth curve KN 17 6v*9c; ABS Control = $0.0051 + 0.0155^*x$; 0.95 Conf. Int.; ABS 50 = $0.0419 + 0.0003^*x$; 0.95 Conf. Int.; ABS 100 = $0.0706 + 0.0095^*x$; 0.95 Conf. Int.; ABS 250 = $0.072 + 0.0104^*x$; 0.95 Conf. Int.; ABS 500 = $0.1044 + 0.0082^*x$; 0.95 Conf. Int. (B) *S. mutans*, Scatterplot of multiple variables against Time. ??????1 in *S. mutans* growth curve KN 17 6v*9c; ABS Control = $0.0359 + 0.0394^*x$; 0.95 Conf. Int.; ABS 50 = $0.0005 + 0.0175^*x$; 0.95 Conf. Int.; ABS 100 = $0.0227 + 0.0097^*x$; 0.95 Conf. Int.; ABS 250 = $0.051 + 0.0035^*x$; 0.95 Conf. Int.; ABS 500 = $0.0854 - 0.0024^*x$; 0.95 Conf. Int. (C) *S. aureus*, Scatterplot of multiple variables against Time. ??????1 in *S. aureus* growth curve KN 17 6v*9c; ABS Control = $-0.0034 + 0.0087^*x$; 0.95 Conf. Int.; ABS 50 = $0.0436 - 0.0039^*x$; 0.95 Conf. Int.; ABS 100 = $0.0513 - 0.0045^*x$; 0.95 Conf. Int.; ABS 250 = $0.0895 - 0.0068^*x$; 0.95 Conf. Int.; ABS 500 = $0.1548 - 0.0041^*x$; 0.95 Conf. Int. (D) *M. luteus*, Scatterplot of multiple variables against Time. ??????1 in *M. luteus* growth curve KN 17 6v*9c; ABS Control = $-0.0289 + 0.0255^*x$; 0.95 Conf. Int.; ABS 50 = $-0.0167 + 0.0228^*x$; 0.95 Conf. Int.; ABS 100 = $0.0615 + 0.0111^*x$; 0.95 Conf. Int.; ABS 250 = $0.0517 + 0.0028^*x$; 0.95 Conf. Int.; ABS 500 = $0.0611 - 0.0027^*x$; 0.95 Conf. Int. (E) *B. cereus*, Scatterplot of multiple variables against Time. ??????1 in *B. cereus* growth curve KN 17 6v*9c; ABS Control = $-0.0278 + 0.0633^*x$; 0.95 Conf. Int.; ABS 50 = $0.0784 + 0.0182^*x$; 0.95 Conf. Int.; ABS 100 = $0.1701 - 0.0055^*x$; 0.95 Conf. Int.; ABS 250 = $0.0951 + 0.0029^*x$; 0.95 Conf. Int.; ABS 500 = $2.0464 - 0.1376^*x$; 0.95 Conf. Int. (F) *S. typhimurium*, Scatterplot of multiple variables against Time. ??????1 in *S. typhimurium* growth curve KN 17 6v*9c; ABS Control = $-0.0165 + 0.0264^*x$; 0.95 Conf. Int.; ABS 50 = $-0.034 + 0.0502^*x$; 0.95 Conf. Int.; ABS 100 = $0.0272 + 0.0225^*x$; 0.95 Conf. Int.; ABS 250 = $0.0232 + 0.0296^*x$; 0.95 Conf. Int.; ABS 500 = $0.0996 + 0.0173^*x$; 0.95 Conf. Int.

Full-size DOI: 10.7717/peerj.14606/fig-1

Anti-tyrosinase activity

Skin whitening or anti-tyrosinase activity was analyzed using a standard tyrosinase inhibitor assay. *K. galanga* essential oil IC_{50} 14.75 $\mu\text{g/mL}$ emerged as a promising source of skin whitening agent better than standard Kojic acid IC_{50} 17.73 $\mu\text{g/mL}$ (Table 2).

Antioxidant activity

The EMCKG showed antioxidant activity with an IC_{50} value of 15.64 $\mu\text{g/mL}$ as compared to that of standard ascorbic acid 21.24 $\mu\text{g/mL}$ for DPPH assay, 16.93 $\mu\text{g/mL}$ for EMCKG while 21.15 $\mu\text{g/mL}$ for standard ascorbic acid for ABTS assay and 19.29 $\mu\text{g/mL}$ for EMCKG and 30.72 $\mu\text{g/mL}$ for EDTA standard for metal chelating assay (Table 2). The reducing power determination assay revealed that EMCKG exhibited better antioxidant properties than the standard ascorbic acid. The antioxidant activity was found to be dose-dependent and showed maximum activity at a concentration of 30 $\mu\text{g/mL}$ (Fig. 2).




Figure 2 Reducing power activities of ethyl p-methoxycinnamate rich *Kaempferia galanga* essential oil and ascorbic acid. Full-size [DOI: 10.7717/peerj.14606/fig-2](https://doi.org/10.7717/peerj.14606/fig-2)

Table 5 *Allium cepa* root growth test for ethyl p-methoxy cinnamate rich MCKG.

Sample/standard (1 µg/mL)	Root lengths before 72 h of treatment (cm) ± SD	Root lengths after 72 h of treatment (cm) ± SD	Total root growth in 72 h (cm)
EMS	07.72 ± 0.012	07.79 ± 0.001	0.07
Distilled H ₂ O	06.14 ± 0.044	06.91 ± 0.012	0.77
MCKG	06.18 ± 0.042	06.47 ± 0.034	0.29

Note: µg, microgram; mL, millilitre; cm, centimetre; EMS, ethyl methanesulfonate; MCKG, ethyl p-methoxy cinnamate rich *K. galanga* essential oil.

Table 6 Mitotic index calculation for ethyl p-methoxy cinnamate rich *K. galanga* essential oil.

Sample/Standard (1 µg/mL)	MI (%)	Prophase	Metaphase	Anaphase	Telophase
EMS	03.82%	91.43%	08.57%	00.00%	00.00%
Distilled H ₂ O	19.20%	44.92%	30.57%	18.24%	06.27%
MCKG	13.56%	56.38%	28.06%	11.52%	04.04%

Note: µg, microgram; mL, millilitre; MI, mitotic index; EMS, ethyl methanesulfonate; MCKG, ethyl p-methoxycinnamate rich *K. galanga* essential oil.

Genotoxicity activity

The genotoxicity of *K. galanga* essential oil was analyzed using an *Allium cepa* assay. Root growth test showed 0.77, 0.29, and 0.07 cm of total growth after 72 h of treatment with distilled water, *K. galanga* essential oil, and ethyl methanesulfonate respectively (Table 5). The mitotic index value of *K. galanga* essential oil 13.56% again showed as very reliable and non-genotoxic in 1 µg/mL concentration close to distilled water 19.20% (Table 6).

The chromosome aberration test for *K. galanga* essential oil showed an aberration rate of 07.60%, which was very close to distilled water 05.60% but far from EMS 16.80% (Table 7, Fig. 3).

Table 7 Chromosome aberration test for ethyl p-methoxy cinnamate rich MCKG.

Sample/standard (1 µg/mL)	CA (%)	CB	CS	CC	CBr	Mu
EMS	16.80%	28	17	19	8	12
Distilled H ₂ O	05.60%	5	4	3	10	6
MCKG	07.60%	12	5	7	6	8

Note:

µg, microgram; mL, millilitre; CA, Chromosome aberration; CB, Chromosome Bridge; CS, Sticky Chromosome; CC, Clumped Chromosome; CBr, Chromosome Breakage; Mu, Multipolarity; EMS, ethyl methanesulfonate; MCKG, ethyl p-methoxycinnamate rich *K. galanga* essential oil.




Figure 3 Ethyl p-methoxycinnamate rich *K. galanga* essential oil genotoxicity chromosomal aberrations. (A) Chromosome breakage, (B) chromosome bridge, (C) clumped chromosome, (D) sticky chromosomes, and (E) multi-polarity. [Full-size !\[\]\(1627b541dccee26fe3f5c6adc0db39d5_img.jpg\) DOI: 10.7717/peerj.14606/fig-3](https://doi.org/10.7717/peerj.14606/fig-3)

The analysis of variance was enumerated for all the bioactivities for both standards used and the *K. galanga* essential oil (Tables S1.1–S1.7 and S2). The ANOVA reveals the presence of statistically significant differences only for the anticholinesterase activity (Table S1.5). All the other bioactivities were statistically insignificant revealing that the essential oil analyzed and the standards used are interchangeable. The *post hoc* analysis using Tukey HSD test was performed which further confirms the significant differences between standard used and the *K. galanga* essential oil for acetylcholinesterase activity (Table S2). Thus, the *K. galanga* essential oil is interchangeable with the standards used for all the bioactivities except for the anticholinesterase activity.

DISCUSSION

GC/MS analysis of *K. galanga* essential oil

The GC/MS analysis of the present study on EMCKG was ethyl p-methoxy cinnamate rich constituting 66.39% of the total area percentage. As per a previous study on the EMCKG of

the identified compounds the major components identified were ethyl *trans*-cinnamate (31.12%) followed by ethyl *trans*-*p*-methoxycinnamate (14.3%), eucalyptol (10.57%), δ -3-carene (5.12%), and *n*-pentadecane (4.8%), respectively (Lal et al., 2017). While in another study conducted the major compounds were found to be propanoic acid, pentadecane, and ethyl-*p*-methoxycinnamate. The other compounds present in minor amounts were isopropyl cinnamate, 1,8-cineol, dicyclohexyl propanedinitrile, ethyl cyclohexyl acetate, undecanone, 9-hydroxy, 2,7-octadiene-1-yl acetate, 2-nonanone, 4-methyl isopulegone, dipentene dioxide, camphene, *cis*-11-tetradecenyl acetate, camphidine, α -pinene, caryophyllenes, 3,7-dimethoxycoumarin, δ -3-carene, cadinenes, α -terpineol, germacrenes, α -gurjunene, 10 undecyn-1-ol, luteolin and apigenin (Khare, 2004; Othman et al., 2006; Koh, 2009; Sutthanont et al., 2010).

Similar results were obtained in a study where the major compounds present were ethyl-*p*-methoxycinnamate, 1-8-cineole, carvone, methyl cinnamate, pentadecane, borneol, camphene, benzene, and α -pinene present in 31.77%, 23.23%, 11.13%, 9.59%, 6.41%, 2.87%, 2.47%, 1.33% and 1.28% respectively (Tewtrakul et al., 2005). A recent report by Mahanta et al. (2020), reported ethyl *p*-methoxycinnamate as the major compound of *K. galanga* essential oil constituting 61.6% of the essential oil. The previous report is in a similar line to our investigations. However, another report revealed that β -phellandrene followed by α -terpineol, ethyl cinnamate and dihydro β -sesquiphellandrene was the major compounds of *K. galanga* essential oil (Sudibyo, 2000). The present study revealed that the present *K. galanga* essential oil is rich in ethyl *p*-methoxycinnamate which has great industrial applications and could be used for the different pharmaceutical purposes as well as separate the fraction of this important compound as a chip source of ethyl *trans*-*p*-methoxycinnamate.

Anti-inflammatory activity

The present analysis of EMCKG for anti-inflammatory activity revealed potent anti-inflammatory properties of EMCKG which was found to be stronger than that of standard. A previous report on the *K. galanga* leaf essential oil revealed that it possesses a dose-dependent anti-inflammatory effect in rats in concentrations of 30, 100 and 300 mg/kg respectively (Sulaiman et al., 2008). Similarly, another report revealed that the *K. galanga* leaf essential oil displays significant inflammation inhibitory properties in rats at the concentration of 30, 100, and 300 mg/kg (Tewtrakul et al., 2005). *K. galanga*, extracts were also reported to inhibit neutrophil infiltration thereby suppressing the progression of chronic and acute inflammation in rats (Jagadish et al., 2016).

A study on the ethyl-*p*-methoxycinnamate for its anti-inflammatory effect was found to inhibit carrageenan-induced edema in a dose-dependent manner with a minimum inhibitory concentration (MIC) value of 10 mg/kg (Umar et al., 2011). A previous report on *in vitro* assay of ethyl-*p*-methoxycinnamate reported inhibition of cyclooxygenase enzymes 1 (COX-1) (42.9%) and 2 (COX-2) (57.82%) whereas the standard indomethacin similarly inhibited COX-1 (82.8%) and COX-2 (54.6%) (Umar et al., 2012). It was concluded that significant anti-inflammatory potential exhibited by ethyl-*p*-methoxycinnamate was done by the inhibition of angiogenesis, and pro-inflammatory

cytokines in return which inhibited the functioning of endothelial cells. The study revealed that ethyl-*p*-methoxycinnamate could be an effective source as a therapeutic agent for the treatment of inflammatory-related disorders (Umar et al., 2014).

In another study, the petroleum ether, a crude alcoholic extract of *K. galanga* was found to have the maximum quantity of ethyl-*p*-methoxycinnamate. Against acute inflammation, in rats, petroleum ether extract was found effective at 300 mg/kg concentration. While petroleum ether extract at a concentration of 100 mg/kg was found to effectively reverse the inflammation (Jagadish et al., 2016). In a study that reported the alcoholic extract the anti-inflammatory activity of *K. galanga* was analyzed in animal models. In the study, two doses of plant extract exhibited significant inflammation-reducing capacity in the cotton pellet granuloma model and carrageenan model in 600 and 1,200 mg/kg doses (Vittalrao et al., 2011). When the aqueous extracts of *K. galanga* leaves were given subcutaneously they displayed significant inflammation-inhibitory properties in rats in a dose-dependent manner (Sulaiman et al., 2008). The presence of high ethyl *p*-methoxycinnamate content can be attributed as the reason for the significant anti-inflammatory activity as various previous studies have also shown its anti-inflammatory activities. Hence the study reveals the high anti-inflammatory activity of EMCKG which can be potentially used and further validates the application of *K. galanga* in ethnomedicine for its anti-inflammatory properties.

Antimicrobial activity

EMCKG was found to exhibit antimicrobial activity in a concentration-dependent manner. While the MIC and growth curve experiment revealed better antibacterial properties than antifungal properties of EMCKG. Previous studies revealed that extracts of *K. galanga* from which ethyl-*p*-methoxycinnamate was isolated have significant activities against *Candida albicans* and *Mycobacterium tuberculosis* (Kanjapothi et al., 2004; Techaprasan et al., 2010). Moreover, resazurin microtitre assay of ethyl-*p*-methoxycinnamate revealed its capacity to inhibit multidrug-resistant and drug-susceptible strains of *M. tuberculosis* (MIC 0.242 to 0.485 mM) (Lakshmanan et al., 2011). Another study revealed the antimicrobial activity of *K. galanga* extracts against selected microbial strains of *Escherichia coli*, *Klebsiella pneumonia*, *Serratia marcescens*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Vibrios parahaemolyticus*, *Candida albicans*, *Vibrios cholera*, *Enterococcus faecalis* and *Salmonella typhi* (Mekseepralard, Kamkaen & Wilinson, 2010). *Kaempferia galanga* rhizome extract ethyl-*p*-methoxy cinnamate was screened for its antibacterial activity which revealed that concentrations up to 1.2% and 2.4% have a minimum inhibitory concentration (MIC) against *S. epidermidis* and *S. aureus*; while for *P. acne*, the concentrations are 0.6%, 1.2%, and 2.4% (Dash, Nasrin & Ali, 2014). Another study reported that the aqueous extracts, methanol, ethanol, chloroform and petroleum ether of *K. galanga* possess microbial growth inhibition against *Enterobacter aerogenes*, *Staphylococcus aureus*, *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, *Bacillus cereus*, *Streptococcus faecalis*, *Pseudomonas aeruginosa*, *Candida albicans*, *Klebsiella pneumoniae*, *Vibrio cholera*, *Aspergillus niger*, *A. fumigatus*, and *A. flavus* (Elya et al., 2016). However, Samsol et al. (2021), reported that *Kaempferia*

galanga essential oil exhibited low activity against *Bacillus subtilis*, *Bacillus cereus*, *Klebsiella pneumoniae*, *Aspergillus spp* and *Saccharomyces cerevisiae*.

[Tewtrakul et al. \(2005\)](#), reported that the EMCKG exhibited marked antimicrobial activity against *C. albicans*, gram-negative, positive bacteria with the zone of inhibition of 31.0, 8.0–12.0 and 12.0–16.0 mm respectively. It was found to be stronger than that of standard antifungal Clotrimazole which had an inhibition zone of 25.0 mm against *C. albicans* ([Tewtrakul et al., 2005](#)). The present findings thus revealed that EMCKG possesses more potent antimicrobial activity which is comparable to that of the standards used in the study. EMCKG thus has the scope to be used as an antimicrobial agent with better potential as an antibacterial agent as compared to the antifungal potential.

Anti-cholinesterase activity

Anticholinesterase activity revealed that EMCKG was comparable to that of standard. So far, the acetylcholinesterase activity for *K. galanga* essential oil has not been studied. However, a study on the methanolic extract of *K. parviflora* as well as its compounds was conducted which revealed that it inhibited butyryl cholinesterase (BChE) and acetylcholinesterase (AChE). This study is significant in Alzheimer's disease treatment ([Sawasdee et al., 2009](#)). Thus, EMCKG possesses potential to be used for the acetylcholinesterase property with further evaluation.

Anti-diabetic activity

The present study on the anti-diabetic activity of EMCKG revealed EMCKG possess potent anti-diabetic property and surpassed the standard. There were few studies reported as *K. galanga* rhizome extracts possess anti-diabetic effects that reduce the blood cholesterol level in rats ([Sudatri et al., 2019](#)). The mentioned investigation reported that the decrease in blood cholesterol may be due to the presence of flavonoids. In the present investigation, the anti-diabetic potential of *K. galanga* essential oil could be positively correlated with the presence of triterpenoids, steroids, etc. ([Mohammad et al., 2006](#)). Because triterpenes appear to exhibit sufficient characteristics. Numerous studies have demonstrated that these substances have various anti-diabetic actions. They can normalize plasma glucose and insulin levels, stop the onset of insulin resistance and inhibit enzymes involved in glucose metabolism ([Nazaruk & Borzym-Kluczyk, 2015](#)). Additionally, α -amylase is a primary enzyme in carbohydrate metabolism, hence inhibition of this enzyme activity will inhibit unwanted glucose metabolism thereby preventing blood glucose levels. The previous investigation by [Sudatri et al. \(2019\)](#), hypothesized that the extract activity might be due to flavonoids, but in the present investigation, it is proved that the anti-diabetic activity of EMCKG was totally due to the high content of triterpenoids.

Although reports are available regarding the anti-diabetic potential of *K. galanga* the majority of about rhizome extracts. As different solvent extracts possess different compositions, as well as essential oil composition, differs a lot from those of solvent extracts, hence, the present investigation gives a lot of impacts on the field of a new anti-diabetic agent search. Moreover, to fully validate as well as for the development of a

successful anti-diabetic agent additional pre-clinical and clinical studies should be carried out.

Anti-tyrosinase activity

The anti-tyrosinase activity of EMCKG revealed its strong skin whitening property superior to that of the standard. Earlier, *K. galanga* was reported for its skin disease preventive activities by [Kumar \(2020\)](#). Another study by [Ko et al. \(2014\)](#), on ethyl p-methoxy cinnamate crystals isolated from *K. galanga* chloroform fraction of ethanol extract, was reported for its ability to decrease melanin synthesis in B16F10 murine melanoma cells. But so far there is no report available regarding the skin-whitening activity of *K. galanga* rhizome essential oil. In the present investigation, ECMKG was found to compose of 13 different identified components with different area percentages.

An evaluation of the bioactivity of an individual component and a group of components is different. Recently an investigation showed ethyl cinnamate as a pure compound possesses strong skin whitening activity ([Tepe & Ozaslan, 2020](#)). In the present investigation, ethyl cinnamate composes 15.86% of the total essential oil. Hence, the strong anti-tyrosinase activity of the essential oil may be due to the presence of ethyl cinnamate in such a good quantity. So far, there is no report regarding *K. galanga* essential oil skin whitening activity available in the public domain making this the first-ever report. The findings also support the traditional use of the plant for various skin-related treatments. The strong anti-tyrosinase potential of the EMCKG makes way for the formulation and design of new skin whitening agents in the field of pharmaceuticals with easy availability, a cost-effective way.

Antioxidant activity

The EMCKG showed more potent antioxidant properties than that of standard in the entire assay conducted for testing the antioxidant potential. A previous study on the rhizomes and leaves ethanolic extracts of *K. galanga* revealed that the antioxidant activity was found to be 77 mg ascorbic acid (AA)/100 g for leaves and 17 mg AA/100 g for rhizome respectively ([Chan et al., 2008](#)). In another study, the essential oil of (CP) conventionally propagated and (IVP) *in vitro* propagated plant of *K. galanga* was screened for DPPH scavenging activity. The study revealed the antioxidant activity was concentration-dependent with IC₅₀ values, 6.6 (ascorbic acid), 26 (CP rhizome), and 19.5 µg/mL (IVP rhizome). Additionally, the hydrogen peroxide scavenging activity revealed a similar good antioxidant property against H₂O₂, with IC₅₀ values of 29 (for essential oil samples of CP rhizome), 24.5 (for oil samples of IVP rhizome), and 21.5 µg/mL (for ascorbic acid) ([Sahoo et al., 2014](#)). A previous report by [Ali et al. \(2018\)](#) reported on the DPPH, ABTS and nitric oxide (NO) scavenging activity with IC₅₀ values of 16.58, 8.24 and 38.16 µg/mL in DPPH, ABTS and no scavenging assays respectively. [Chan & Lee \(2019\)](#) reported that DPPH and ABTS radical scavenging activity in *Kaempferia galanga* increased in a concentration-dependent manner which is in a similar line to our findings. However, another study revealed weak anti-oxidant properties of *K. galanga* extracts ([Mekseepalard, Kamkaen & Wilinson, 2010](#)). Similarly, another study reported

on the EMCKG that the antioxidant activity (DPPH assay) was inactive at a concentration of 100 µg/mL (*Tewtrakul et al., 2005*). The metal chelating activity on *Kaempferia galanga* was not previously reported by any findings thereof our result is the first report on antioxidant activity on ethyl p-methoxycinnamate rich *K. galanga* with the metal chelating assay. Our finding revealed that EMCKG has better antioxidant properties as compared to standard antioxidative agent ascorbic acid and further validates the ethnomedicinal use of *K. galanga*. The presence of high ethyl p-methoxycinnamate content may be the underlying reason for the high antioxidant activity of EMCKG. Additionally, as mentioned in the previous paragraph EMCKG was found to be an active inhibitor of the α -amylase enzyme, which property has a direct link with the anti-oxidant property of EMCKG. As there are evidence that ROS can react with insulin secreting β -cells thereby maximizing the chance of the development of diabetic condition (*Fu et al., 2013*). Hence a good antioxidant could be a good anti-diabetic agent. Thus, it can be concluded that EMCKG can be further analyzed for its use as a natural source of the antioxidative agent.

Genotoxicity activity

Genotoxicity assay of EMCKG made it clear that at 1 µg/mL concentration the use of *K. galanga* essential oil is safe as it did not affect much the mitotic index and chromosomal aberration rates in the *Allium cepa* assay. So far, *K. galanga* crude rhizome extracts were tested for various toxicological studies such as contact toxicity, insecticidal effects, acute and sub-acute toxicities in rats, etc. (*Kanjanapothi et al., 2004*). So far there is no report available regarding the genotoxicity of *K. galanga* essential oil and this present report is the first of its kind. The present investigation showed that up to the concentration of 1 µg/mL the essential oil does not possess any genotoxic effect. Hence, this investigation result could give a safety tag of up to 1 µg/mL concentration of the essential oil. Therefore, in the near future formulation of the drug with potential effects could be designed by limiting the concentration up to the safety mark.

CONCLUSIONS

The studied *K. galanga* rhizome essential oil was found to be rich in ethyl p-methoxycinnamate. Thus, an ethyl p-methoxycinnamate rich variety of *K. galanga* would be highly valuable and is required to meet the high industrial demand for raw materials for ethyl p-methoxycinnamate. The essential oil was found to possess a significant number of bioactivities like antioxidant, anti-inflammation, neurodegenerative disorders inhibitor, anti-diabetic, skin whitening as well as antimicrobial potential which further increases its pharmaceutical and industrial value in addition to validating its ethnopharmacological application. The essential oil also emerged as a very suitable source for raw materials in the formulation of anti-diabetic, skin whitening agents. From a toxicological point of view, the essential oil was found to be safe up to the concentration of 1 µg/mL. For the use of essential oil to formulate products or drugs it needs to go through further pre-clinical as well as deep clinical trials.

ACKNOWLEDGEMENTS

The authors are thankful to the director CSIR-North East Institute of Science and Technology, Jorhat, Assam (India), for allowing and providing us with the facilities for the smooth conduct of this research work.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by NMPB, New Delhi (India), project No. R&D/AS/01-2019-20. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
NMPB, New Delhi (India): R&D/AS/01-2019-20.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Twahira Begum conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Roktim Gogoi performed the experiments, analyzed the data, prepared figures and/or tables, and approved the final draft.
- Neelav Sarma performed the experiments, prepared figures and/or tables, and approved the final draft.
- Sudin Kumar Pandey analyzed the data, prepared figures and/or tables, and approved the final draft.
- Mohan Lal conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:
The raw data is available in the [Supplemental File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.14606#supplemental-information>.

REFERENCES

Aiyelaagbe OO, Osamudiamen PM. 2009. Phytochemical screening for active compounds in *Mangifera indica* leaves from Ibadan, Oyo state. *Plant Sciences Research* 2(1):11–13.

- Ali H, Yesmin R, Satter A, Habib R, Yeasmin T. 2018. Antioxidant and antineoplastic activities of methanolic extract of *Kaempferia galanga* Linn. rhizome against Ehrlich ascites carcinoma cells. *Journal of King Saud University–Science* 30(3):386–392 DOI 10.1016/j.jksus.2017.05.009.
- Begum T, Gogoi R, Lal M. 2020. Ginger: an important cash crop for hilly region of India. In: Swami S, ed. *Advanced of Hill Agriculture*. Vol. 3. New Delhi: AkiNik publications, 39–61.
- Begum T, Gogoi R, Sarma N, Pandey SK, Lal M. 2022. Direct sunlight and partial shading alter the quality, quantity, biochemical activities of *Kaempferia parviflora* Wall., ex Baker rhizome essential oil: a high industrially important species. *Industrial Crops & Products* 180:114765 DOI 10.1016/j.indcrop.2022.114765.
- Chan CYV, Lee J. 2019. Anti-inflammatory and antioxidant effects of hot water extracts from *Kaempferia galanga* L. *Journal of Convergence for Information Technology* 9(6):218–226 DOI 10.22156/CS4SMB.2019.9.6.218.
- Chan EWC, Lim YY, Wong LF, Lianto FS, Wong SK, Lim KK, Joe CE, Lim TY. 2008. Antioxidant and tyrosinase inhibition properties of leaves and rhizomes of ginger species. *Food Chemistry* 109:477–483 DOI 10.1016/j.foodchem.2008.02.016.
- Chan EWC, Lim YY, Wong SK, Lim KK, Tan SP, Lianto FS, Yong MY. 2009. Effects of different drying methods on the antioxidant properties of leaves and tea of ginger species. *Food Chemistry* 113:166–172 DOI 10.1016/j.foodchem.2008.07.090.
- Choochote W, Kanjanapothi D, Panthanga A, Taesotikul T, Jitpakdi A, Chaithong U, Pitasawat B. 1999. Larvicidal and repellent effects of *Kaempferia galanga*. *The Southeast Asian Journal of Tropical Medicine and Public Health* 30(3):470–476.
- Dash PR, Nasrin M, Ali M. 2014. *In vivo* cytotoxic and *in vitro* antibacterial activities of *Kaempferia galanga*. *Journal of Pharmacognosy and Phytochemistry* 3(1):172–177.
- Dutta P, Sarma N, Saikia S, Gogoi R, Begum T, Lal M. 2021. Pharmacological activity of *Trachys permumammi* L. seeds essential oil grown from Northeast India. *Journal of Essential Oil Bearing Plants* 24(6):1373–1388 DOI 10.1080/0972060X.2022.2028681.
- Elya B, Kusuma IM, Jufri M, Handayani R. 2016. Antibacterial tests against acne in vitro, the physical stability and patch test using cream containing ethyl p-methoxycinnamate extracted from *Kaempferia galanga* L., rhizome. *Research Journal of Medicinal Plants* 10(8):426–434 DOI 10.3923/rjmp.2016.426.434.
- Fu J, Zhang Q, Woods CG, Zheng H, Yang B, Qu W, Andersen M, Pi J. 2013. Divergent effects of sulforaphane on basal and glucose stimulated insulin secretion in β -cells: role of reactive oxygen species and induction of endogenous antioxidants. *Pharmaceutical Research* 30:2248–2259 DOI 10.1007/s11095-013-1013-8.
- Geetha SP, Manjula C, John CZ, Minoo D, Nirmal BK, Ravindran PN. 1997. Micropropagation of *Kaempferia* spp. (*K. galanga* and *K. rotunda* L.). *Journal of Spices and Aromatic Crops* 6(2):129–135.
- Gogoi R, Begum T, Lal M. 2020. Prospects of essential oils in pharmacological applications with sustainable development strategies of hilly regions of India. In: Swami S, ed. *Advances in Hill Agriculture*. Vol. 3. New Delhi: AkiNik publications, 63–84.
- Gogoi R, Sarma N, Begum T, Pandey SK, Lal M. 2020b. North-East Indian *Chromolaena odorata* (L. King Robinson) aerial part essential oil chemical composition, pharmacological activities–neurodegenerative inhibitory and toxicity study. *Journal of Essential Oil Bearing Plants* 23(6):1173–1191 DOI 10.1080/0972060X.2020.1867009.
- Gogoi R, Sarma N, Twahira B, Pandey SK, Lal M. 2020a. Comparative in-vitro biological activities of methyl eugenol rich *Cymbopogon khasianus* Hack., leaf essential oil with pure

- methyl eugenol compound. *Current Pharmaceutical Biotechnology* **21**(10):927–938
DOI [10.2174/1389201021666200217113921](https://doi.org/10.2174/1389201021666200217113921).
- Goodner KL. 2007.** Practical retention index models of OV-101, DB-1, DB-5, and DB-Wax for flavor and fragrance compounds. *LWT* **41**:951–958 DOI [10.1016/j.lwt.2007.07.007](https://doi.org/10.1016/j.lwt.2007.07.007).
- Hong TK, Kim SI, Heo JW, Lee JK, Choi DR, Ahn YJ. 2011.** Toxicity of *Kaempferia galanga* rhizome constituents to *Meloidogyne incognita* juveniles and eggs. *Nematology* **13**:235–244
DOI [10.1163/138855410X517048](https://doi.org/10.1163/138855410X517048).
- Hu SY. 2005.** *Food plants of China*. Hong Kong: The Chinese University Press, 328–329.
- Huang J, Qian C, Xu H, Huang Y. 2018.** Antibacterial activity of *Artemisia asiatica* essential oil against some common respiratory infection causing bacterial strains and its mechanism of action in *Haemophilus influenzae*. *Microbial Pathogenesis* **114**:470–475
DOI [10.1016/j.micpath.2017.12.032](https://doi.org/10.1016/j.micpath.2017.12.032).
- Huang L, Yagura T, Chen S. 2008.** Sedative activity of hexane extract of *Kaempferia galanga* L. and its active compounds. *Journal of Ethnopharmacology* **120**:123–125
DOI [10.1016/j.jep.2008.07.045](https://doi.org/10.1016/j.jep.2008.07.045).
- Jagadish PC, Latha KP, Mudgal J, Nampurath GK. 2016.** Extraction, characterization and evaluation of *Kaempferia galanga* L. (*Zingiberaceae*) rhizome extracts against acute and chronic inflammation in rats. *Journal of Ethnopharmacology* **194**:434–439
DOI [10.1016/j.jep.2016.10.010](https://doi.org/10.1016/j.jep.2016.10.010).
- Jitoe A, Masuda T, Tengah IGP, Suprapta DN, Gara IW, Nakatani N. 1992.** Antioxidant activity of tropical ginger extract and analysis of the contained curcuminoids. *Journal of Agricultural and Food Chemistry* **40**(8):1337–1340 DOI [10.1021/jf00020a008](https://doi.org/10.1021/jf00020a008).
- Kanjanapothi D, Panthong A, Lertprasertsuke N, Taesotikul T, Rujjanawate C, Kaewpinit D, Sudthayakorn R, Choochote W, Chaithong U, Jitpakdi A, Pitasawat B. 2004.** Toxicity of crude rhizome extract of *Kaempferia galanga* L. (ProhHom). *Journal of Ethnopharmacology* **90**:359–365 DOI [10.1016/j.jep.2003.10.020](https://doi.org/10.1016/j.jep.2003.10.020).
- Karioti A, Protopappa A, Megoulas N, Skaltsa H. 2007.** Identification of tyrosinase inhibitors from *Marrubiumvelutinum* and *Marrubiumcylleum*. *Bioorganic & Medicinal Chemistry* **15**:2708–2714 DOI [10.1016/j.bmc.2007.01.035](https://doi.org/10.1016/j.bmc.2007.01.035).
- Khare CP. 2004.** *Indian herbal remedies: rational western therapy, ayurvedic, and other traditional usage and botany*. Vol. 275. Berlin: Springer-Verlag, 65–67.
- Kim NJ, Byun SG, Cho JE, Chung K, Ahn YJ. 2008.** Larvicidal activity of *Kaempferia galanga* rhizome phenylpropanoids towards three mosquito species. *Pest Management Science* **64**:857–862 DOI [10.1002/ps.1557](https://doi.org/10.1002/ps.1557).
- Ko HJ, Kim HJ, Kim SY, Yun HY, Baek KJ, Kwon NS, Whang WK, Choi HR, Park KC, Kim DS. 2014.** Hypopigmentary effects of ethyl p-methoxycinnamate isolated from *Kaempferia galanga*. *Phytotherapy Research* **28**:274–279 DOI [10.1002/ptr.4995](https://doi.org/10.1002/ptr.4995).
- Koh HL. 2009.** *Guide to medicinal plants: an illustrated scientific and medicinal approach*. Singapore: World Scientific.
- Kovats E. 1965.** Gas chromatographic characterization of organic substances in the retention index system. *Advances in Chromatography* **1**:229–247.
- Kumar A. 2020.** Phytochemistry, pharmacological activities and uses of traditional medicinal plant *Kaempferia galanga* L.—an overview. *Journal of Ethnopharmacology* **253**:112667
DOI [10.1016/j.jep.2020.112667](https://doi.org/10.1016/j.jep.2020.112667).
- Lakshmanan D, Werngren J, Jose L, Suja KP, Nair MS, Varma RL, Mundayoor S, Hoffner S, Kumar RA. 2011.** Ethyl p-methoxycinnamate isolated from a traditional anti-tuberculosis

- medicinal herb inhibits drug resistant strains of *Mycobacterium tuberculosis in vitro*. *Fitoterapia* **82**:757–761 DOI [10.1016/j.fitote.2011.03.006](https://doi.org/10.1016/j.fitote.2011.03.006).
- Lal M. 2019a.** Bharamputra-1 (IC0610826; INGR17081), an aromatic ginger (*Kaempferia galanga*) germplasm with high rhizome yield (10 tones/ha) and dry rhizome recovery. High essential oil. *Indian Journal of Plant Genetic Resources* **32**(2):284–285.
- Lal M. 2019b.** Jor Lab K-1 (IC0625983; INGR18038), a galanga (*Kaempferia galanga*) germplasm with higher essential oil yield 2.31%. Higher rhizome yield 6.75 tones/ha/year. Higher rhizome yield 6.75 tones/ha/year. Higher dry rhizome recovery 27.50%. *Indian Journal of Plant Genetic Resources* **32**(3):446–447.
- Lal M, Munda S, Dutta S, Baruah J, Pandey SK. 2017.** Identification of the new high oil and rhizome yielding variety of *Kaempferia galanga* (Jor Lab K-1): a highly important indigenous medicinal plants of North East India. *Journal of Essential Oil Bearing Plants* **20**(5):1275–1282 DOI [10.1080/0972060X.2017.1400405](https://doi.org/10.1080/0972060X.2017.1400405).
- Liu B, Liu F, Chen C, Gao H. 2010.** Supercritical carbon dioxide extraction of ethyl p-methoxycinnamate from *Kaempferia galanga* L. rhizome and its apoptotic induction in human HepG2 cells. *Natural Product Research* **24**:1927–1932 DOI [10.1080/14786419.2010.490913](https://doi.org/10.1080/14786419.2010.490913).
- Mahanta BP, Sarma N, Kemprai P, Begum T, Saikia L, Lal M, Haldar S. 2020.** Hydrodistillation based multifaceted value addition to *Kaempferia galanga* L. leaves, an agricultural residue. *Industrial Crops & Products* **154**:112642 DOI [10.1016/j.indcrop.2020.112642](https://doi.org/10.1016/j.indcrop.2020.112642).
- Maisuthisakul P, Gordon MH. 2009.** Antioxidant and tyrosinase inhibitory activity of mango seed kernel by product. *Food Chemistry* **117**:332–341 DOI [10.1016/j.foodchem.2009.04.010](https://doi.org/10.1016/j.foodchem.2009.04.010).
- Mangaly JK, Sabu M. 1991.** Ethanobotany of zingiberaceae. In: *Zingiberaceae Workshop*, Vol. 24. Thailand: Prince of Songkla University, 15–18.
- Mekseepralard C, Kamkaen N, Wilinson JM. 2010.** Antimicrobial and antioxidant activities of traditional Thai herbal remedies for aphthous ulcers. *Phytotherapy Research* **24**:1514–1519 DOI [10.1002/ptr.3158](https://doi.org/10.1002/ptr.3158).
- Mitra R, Orbell J, Muralitharan MS. 2007.** Agriculture—medicinal plants of Malaysia. *Asia-Pacific Biotech News* **11**(2):105–110 DOI [10.1142/S0219030307000110](https://doi.org/10.1142/S0219030307000110).
- Miyazawa M, Oshima T, Koshio K, Itsuzaki Y, Anzai J. 2003.** Tyrosinase inhibitor from black rice bran. *Journal of Agricultural and Food Chemistry* **51**:6953–6956 DOI [10.1021/jf030388s](https://doi.org/10.1021/jf030388s).
- Mohammad SP, Harindran J, Kannaki KS, Revathy R. 2006.** Deuretic activity of *Kaempferiagalanga* Linn. rhizome extract in albino rats. *World Journal of Pharmacy and Pharmaceutical Sciences* **4**(4):1161–1169 DOI [10.20959/wjpps20164-6327](https://doi.org/10.20959/wjpps20164-6327).
- Munda S, Saikia P, Lal M. 2018.** Chemical composition and biological activity of essential oil of *Kaempferia galanga*: a review. *Journal of Essential Oil Research* **30**(5):303–308 DOI [10.1080/10412905.2018.1486240](https://doi.org/10.1080/10412905.2018.1486240).
- Nazaruk J, Borzym-Kluczyk M. 2015.** The role of triterpenes in the management of diabetes mellitus and its complications. *Phytochemistry Reviews* **14**(4):675–690 DOI [10.1007/s11101-014-9369-x](https://doi.org/10.1007/s11101-014-9369-x).
- Ogiso A, Kobayashi S. 1994.** Anti-ulcer agents from Alpina seeds. *Chemical Abstracts* **81**(12):339.
- Othman R, Ibrahim H, Mohd MA, Awang K, Gilani AUH, Musthafa MR. 2002.** Vaso relaxant effect of *Kaempferia galanga* on smooth muscles of the rat aorta. *Planta Medica* **68**(7):655–657 DOI [10.1055/s-2002-32900](https://doi.org/10.1055/s-2002-32900).
- Othman R, Ibrahim H, Mohd MA, Mustafa MR, Awang K. 2006.** Bioassay-guided isolation of a vasorelaxant active compound from *Kaempferia galanga* L. *Phytomedicine* **13**:61–66 DOI [10.1016/j.phymed.2004.07.004](https://doi.org/10.1016/j.phymed.2004.07.004).

- Pandey SK, Gogoi R, Bhandari S, Sarma N, Begum T, Munda S, Lal M. 2022.** A comparative study on chemical composition, pharmacological potential and toxicity of *Pogostemon cablin* Linn., (Patchouli) flower and leaf essential oil. *Journal of Essential Oil Bearing Plants* **25(1)**:160–179 DOI [10.1080/0972060X.2021.2013325](https://doi.org/10.1080/0972060X.2021.2013325).
- Pandji C, Grimm C, Wray V, Witte L, Proksch P. 1993.** Insecticidal constitute from four species of the Zingiberaceae. *Phytochemistry* **34**:415–419 DOI [10.1016/0031-9422\(93\)80020-S](https://doi.org/10.1016/0031-9422(93)80020-S).
- Riditid W, Sae CW, Reanmongkol W, Wongnawa M. 2008.** Antinociceptive activity of the methanolic extract of *Kaempferia galanga* Linn. in experimental animals. *Journal of Ethnopharmacology* **118(2)**:225–230 DOI [10.1016/j.jep.2008.04.002](https://doi.org/10.1016/j.jep.2008.04.002).
- Sahoo S, Parida R, Singh S, Padhy RN, Nayak S. 2014.** Evaluation of yield, quality and antioxidant activity of essential oil of in vitro propagated *Kaempferia galanga* Linn. *Journal of Acute Disease* **3(2)**:124–130 DOI [10.1016/S2221-6189\(14\)60028-7](https://doi.org/10.1016/S2221-6189(14)60028-7).
- Samsol Z, Iskandar MI, Ariffin ZZ, Safian MF. 2021.** Chemical constituents, antioxidant and antimicrobial activities of *Kaempferia galanga* rhizome essential oils. *International Journal of Social Science Research* **3(4)**:405–419.
- Sawasdee P, Sabphon C, Sitthiwongwanit D, Kokpol U. 2009.** Anticholinesterase activity of 7-methoxyflavones isolated from *Kaempferia parviflora*. *Phytotherapy Research* **23**:1792–1794 DOI [10.1002/ptr.2858](https://doi.org/10.1002/ptr.2858).
- Sudatri NIW, Wirasiti N, Suartini NIM, Bidura IGNG. 2019.** Anti-diabetic and anti-cholesterol activity of *Kaempferia galanga* L. herbal medicine rhizome in albino rats. *International Journal of Fauna and Biological Studies* **6(5)**:13–17.
- Sudibyo RS. 2000.** The content of volatile oil isolated from *Kaempferia galanga* rhizome. Mass spectroscopic approach. *Majalah Farmasi Indonesia* **11(3)**:142–149.
- Sulaiman MR, Zakaria ZA, Daud IA, Ng FN, Ng YC, Hidayat MT. 2008.** Antinociceptive and anti-inflammatory activities of the aqueous extract of *Kaempferia galanga* leaves in animal models. *Journal of Natural Medicines* **62**:221–227 DOI [10.1007/s11418-007-0210-3](https://doi.org/10.1007/s11418-007-0210-3).
- Sutthantont N, Choochote W, Tuetun B, Junkum A, Jitpakdi A, Chaithong U, Riyong D, Pitasawat B. 2010.** Chemical composition and larvicidal activity of edible plant-derived essential oils against the pyrethroid susceptible and -resistant strains of *Aedes aegypti* (Diptera: Culicidae). *Journal of Vector Ecology* **35**:106–115.
- Taufikkurohmah T. 2005.** Synthesis of p-methoxycinnamate p-methoxycinnamate from ethyl p-methoxycinnamate isolation of kencur rhizome (*Kaempferia galanga* L) as candidate of sunscreen. *Indonesian Journal of Chemistry* **5(3)**:193–197.
- Techaprasan J, Klinbunga S, Ngamriabsakul C, Jenjittikul T. 2010.** Genetic variation of *Kaempferia* (Zingiberaceae) in Thailand based on chloroplast DNA (psbA-trnH and petA-psbJ) sequences. *Genetics and Molecular Research* **9**:1957–1973 DOI [10.4238/vol9-4gmr873](https://doi.org/10.4238/vol9-4gmr873).
- Tepe AS, Ozaslan M. 2020.** Anti-alzheimer, anti-diabetic, skin-whitening, and antioxidant activities of the essential oil of *Cinnamomum zeylanicum*. *Industrial Crops & Products* **145**:112069 DOI [10.1016/j.indcrop.2019.112069](https://doi.org/10.1016/j.indcrop.2019.112069).
- Tewtrakul S, Yuenyongsawawad S, Kummee S, Atsawajaruwan I. 2005.** Chemical components and biological activities of volatile oil of *Kaempferia galanga* Linn. *Songklanakarin Journal of Science and Technology* **27(2)**:503–507.
- Umar MI, Asmawi MZB, Sadikun A, Altar F, Iqbal MA. 2011.** Phytochemistry and medicinal properties of *Kaempferia galanga* L. (Zingiberaceae) extracts. *African Journal of Pharmacy and Pharmacology* **5(14)**:1638–1647 DOI [10.5897/AJPP11.388](https://doi.org/10.5897/AJPP11.388).

- Umar MI, Asmawi MZ, Sadikun A, Atangwho IJ, Yam MF, Altaf R, Ahmed A. 2012.** Bioactivity-guided isolation of ethyl-p-methoxycinnamate, an anti-inflammatory constituent, from *Kaempferia galanga* L. extracts. *Molecules* **17**:8720–8734 DOI [10.3390/molecules17078720](https://doi.org/10.3390/molecules17078720).
- Umar MI, Asmawi MZ, Sadikun A, Majid AMSA, Al-Suede FSR, Hassan LEA, Altaf R, Ahamed MBK. 2014.** Ethyl-p-methoxycinnamate isolated from *Kaempferia galanga* inhibits inflammation by suppressing interleukin-1, tumor necrosis factor- α , and angiogenesis by blocking endothelial functions. *Clinics* **69**(2):134–144 DOI [10.6061/clinics/2014\(02\)10](https://doi.org/10.6061/clinics/2014(02)10).
- Vittalrao AM, Shanbhag T, Kumari M, Bairy KL, Shenoy S. 2011.** Evaluation of anti-inflammatory and analgesic activities of alcoholic extract of *Kaempferia galanga* in rats. *Indian Journal of Physiology and Pharmacology* **55**(1):13–24.